Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma

Lung Cancer

Volumn 83, Issue 3, 2014, Pages 389-395

  Kim, Min Hwan ^a   Shim, Hyo Sup ^b   Kang, Dae Ryong ^b   Jung, Ji Ye ^b   Lee, Chang Young ^b   Kim, Dae Joon ^b   Lee, Jin Gu ^b   Bae, Mi Kyung ^b   Kim, Hye Ryun ^a   Lim, Sun Min ^a   Kim, Eun Young ^b   Park, Ji Soo ^a   Chung, Kyung Young ^b   Kim, Hyun Jung ^c   Kim, Joo Hang ^a   Cho, Byoung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c JE UK Institute for Cancer Research Ltd   (South Korea)

Author keywords

Anaplastic lymphoma kinase; C ros oncogene 1; Lung adenocarcinoma; Never smokers; Prognosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; C-ROS ONCOGENE 1; LUNG ADENOCARCINOMA; NEVER-SMOKERS; PROGNOSIS;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; GENE REARRANGEMENT; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PNEUMONECTOMY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS;

EID: 84894267940     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.003     Document Type: Article

References (31)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Mok T.S., Wu Y.-L., Thongprasert S., Yang C.-H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Paz-Ares L., Sanchez J., Garcia-Velasco A., Massuti B., López-Vivanco G., Provencio M., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006, 24:7020.
4. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
5. Oxnard G.R., Binder A., Jänne P.A. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31:1097-1104.
6. Ju Y.S., Lee W.-C., Shin J.-Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22:436-445.
7. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18:378-381.
8. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
9. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
10. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
11. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
12. Shaw A.T., Kim D.-W., Nakagawa K., Seto T., Crinó L., Ahn M.-J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
13. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
14. Ou S.H.I., Zell J.A., Ziogas A., Anton Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients. Cancer 2007, 110:1532-1541.
15. D'Angelo S.P., Janjigian Y.Y., Ahye N., Riely G.J., Chaft J.E., Sima C.S., et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012, 7:1815-1822.
16. Janjigian Y.Y., Park B.J., Zakowski M.F., Ladanyi M., Pao W., D'Angelo S.P., et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 2011, 6:569-575.
17. Kim H.R., Shim H.S., Chung J.H., Lee Y.J., Hong Y.K., Rha S.Y., et al. Distinct clinical features and outcomes in never smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012, 118:729-739.
18. Fukui T., Yatabe Y., Kobayashi Y., Tomizawa K., Ito S., Hatooka S., et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012, 77:319-325.
19. Pailler E., Adam J., Barthelemy A., Oulhen M., Auger N., Valent A., et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013, 31:2273-2281.
20. Choi H., Paeng J.C., Kim D.W., Lee J.K., Park C.M., Kang K.W., et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer 2013, 79:242-247.
21. Yang P., Kulig K., Boland J.M., Erickson-Johnson M.R., Oliveira A.M., Wampfler J., et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012, 7:90-97.
22. Zhou J.X., Yang H., Deng Q., Gu X., He P., Lin Y., et al. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Ann Oncol 2013, 24:1319-1325.
23. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76:403-409.
24. Kim H.R., Lim S.M., Kim H.J., Hwang S.K., Park J.K., Shin E., et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 2013, 10.1093/annonc/mdt220.
25. Subramanian J., Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007, 25:561-570.
26. Lee Y.J., Kim J.H., Kim S.K., Ha S.J., Mok T.S., Mitsudomi T., et al. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 2011, 72:9-15.
27. Li C., Fang R., Sun Y., Han X., Li F., Gao B., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011, 6:e28204.
28. Roskoski R. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 2013, 68:68-94.
29. Murakami S., Yokose T., Saito H., Sakuma Y., Matsukuma S., Hasegawa C., et al. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer 2010, 69:361-364.
30. Tomizawa K., Ito S., Suda K., Fukui T., Usami N., Hatooka S., et al. Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval. Lung Cancer 2013, 80:99-101.
31. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.